(MENAFN- GlobeNewsWire - Nasdaq) 70% of Noom members receiving microdoses of GLP-1 with lifestyle support report no side effects, while experiencing significant weight loss and overall health gains ...

A new program for whole health with Noom and GLP-1s. PRINCETON, N.J., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Noom, the leading platform for preventive health and longevity, today announced the launch of ...

Diet weight loss company Noom announced it is launching a new program dubbed the Noom Microdose GLP-1Rx Program, which will provide members with personalized microdoses of GLP-1 medication. The ...

Ash Provides the At-Home Testing Operational Backbone for Noom’s New Proactive Health Microdose GLP-1 Rx Program, Anchoring Healthy Aging in Biomarker Data and the Science of Healthy Habits NEW YORK, ...

In this episode, MM+M Pharma Editor Lecia Bushak sits down with Noom’s CEO Geoff Cook and Chief Medical Officer Dr. Jeffrey Egler to discuss the launch of their new Microdose GLP-1 program, designed ...

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch ...

New program pairs microdoses of GLP-1 medication with Noom’s powerful behavior-change program and at-home biomarker testing to track the health impact of combining GLP-1 therapy with healthy habits.

PRINCETON, N.J., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Noom, the leading platform for preventive health and longevity, today announced the launch of Proactive Health Microdose GLP-1 Rx, a ...

The MarketWatch News Department was not involved in the creation of this content. New program pairs microdoses of GLP-1 medication with Noom's powerful behavior-change program and at-home biomarker ...